Post by Curium Pharma

Curium is one step closer to advancing access to targeted radioligand therapy for patients with GEP-NETs in the United States after receiving a favorable decision from the U.S. District Court in Delaware.    “With more than 100 years of experience in nuclear medicine and over 30 years of commitment to the NET community, we remain focused on delivering innovative solutions that make a meaningful difference for patients,” said Michael Patterson, CEO, Curium North America.    This is an important milestone for Curium and crucially the patients we serve. https://lnkd.in/eiXreniU   #Curium #NuclearMedicine #Theranostics #NETs #Radiopharmaceuticals